INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. ("Cencora" or the "Company") (NYSE: COR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • 2 hours ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext. 7980.

GlobeNewsWire • Jun 2, 2026

Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel). The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.S., including health systems and community oncology practices.

Business Wire • Jun 2, 2026

Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced pub.

Business Wire • May 27, 2026

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.

Zacks Investment Research • May 27, 2026

Cencora revises forecast for 2026, approves $2 billion share buyback

U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal ​2026 earnings forecast citing recent ‌share repurchases, and also approved a new $2 billion stock buyback plan.

Reuters • May 21, 2026

Cencora Announces Updated Fiscal Year 2026 Financial Outlook

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted diluted earnings per share to be in the range of $17.70 to $17.90, up from the previous range of $17.65 to $17.90. The opportunistic share repurchases completed in May align with the Company's previously disclosed expectation that it will repurchase $1.0 billion in shares of common stock by the end.

Business Wire • May 21, 2026

COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, May 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or “the Company”) (NYSE: COR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire • May 18, 2026

Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cencora, Inc. (NYSE: COR) resulting from allegations that Cencora may have issued materially misleading business information to the investing public. So What: If you purchased Cencora securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.

Business Wire • May 15, 2026

Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Cencora, Inc. (COR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026